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The pattern of antibiotics use in cancer patients in the intensive care unit 
(ICU) of dharma is cancer special hospital (DCSH) has not been identified. 
The purpose of this study is to determine the pattern of antibiotics use  
in cancer patients treated in the ICU of DCSH from 2012-2014. This study 
was observational with a cross-sectional design. The data collection is done 
retrospectively. The inclusion criteria to recruit the subjects, i.e. Adult patients who 
had nosocomial infections in the ICU; Patients with medical records  
in the ICU who received antibiotics in the 2012-2014 periods.  
Patients originating from inpatients (wards); Patients with medical records 
were read. The exclusion criteria were postoperative patients and Patients 
with incomplete medical records. We collected data from medical records  
of cancer patients who had been admitted to the ICU in 2012-2014,  
medication administration records, sample submission, and laboratory 
records. There are 202 cancer patients including in the study. Leukemia and 
breast cancer were the most cancer’s diagnosis in the Subject. More than two 
hundred cancer patients were receiving antibiotic therapy, with more than 
50% of them were diagnosed with pneumonia, followed by central infection 
(>20%) and urinary tract infection (>10%). The antibiotic most frequently 
used was meropenem, with 33.8%. The three most commonly used 
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Infection contracted in the hospital intensive care unit (ICU) is one of the health problems  
in the world and Indonesia [1, 2]. Research in 11 Indonesian hospitals in 2004 showed that the incidence  
of nosocomial infections was 9.8%. A similar study in 2005-2010 showed that the incidence of hospital  
care-associated infection (HAI) in Indonesia was lower at 7.1% [3]. However, the figure was still higher than 
in China, where the incidence was reported at 3.6% [4]. Patients treated in the ICU generally have a higher 
risk of infections with particular bacterial patterns [5, 6]. Cancer patients have a higher risk of infections 
while undergoing treatment in hospitals, especially in ICU(2). Pathological conditions and chemotherapy 
weaken their immunity so that they are more at risk for infection when they are admitted to ICU.  
Research in DCSH in 2011-2012 in 119 cancer patients treated with a central venous catheter (CVC) shows 
that 18.5% of patients were diagnosed with sepsis, 47.9% with colonization, and 14.3% with bacteremia.  
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The incidence of bloodstream infection related CVC (BSI-CVC) was 13.3%, which occurred mostly  
in patients with hematological malignancies (78.4%) and in impaired-immunity isolation room (90%) [3]. 
Other factors associated with increased risk of infection in ICU patients with cancer include the use  
of invasive health devices such as ventilators and the treatment length [7]. Diseases commonly contracted  
by patients in the ICU are urinary tract infections [8], lower respiratory tract infections [9], and infections due 
to the catheter or central venous infusion use [3, 10]. Until now, antibiotics are still the primary weapon  
to overcome the incidence of infection in the ICU, but the issue of germ resistance to antibiotics raises  
the fear and anxiety of many clinicians. Hospital management requires data on the pattern of antibiotic use 
for policymaking and anticipating resistance events.  
Antibiotics are the first drugs to deal with and prevent the incidence of bacterial infections  
in the hospital, including in the ICU [11-13]. The extent of bacterial resistance to antibiotics in hospitals, 
especially in the ICU, has been widely reported [14, 15]. In the ICU, the resistance tends to occur more 
quickly because of treatment duration and immune system impairment [5, 16]. Several types of antibiotics 
are reported to have resistance events for use in ICU [17, 18]. Antibiotic resistance provides a broad impact 
both for patients, hospitals, and the government. Monitoring antibiotic use patterns is one method of early 
detection of antibiotic resistance events. Data on the use of antibiotic patterns from time to time is one 
important information to predict trends in the incidence of antibiotic resistance in the ICU [19, 20].  
Still, until now, the pattern of antibiotic use in ICU for cancer patients is not enough available in Indonesia. 
The purpose of this study is to determine the pattern of antibiotic use in cancer patients in the ICU of DCSH. 
 
 
2. RESEARCH METHOD 
2.1.  Research design   
This study was an observational, descriptive study with a cross-sectional design. The data collection 
is done retrospectively. Data were collected from medical records of cancer patients who had been admitted 
to the ICU of dharma’s cancer special hospital (ICU of DCSH) in 2012-2014, medication administration 
records, sample submission, and culture examination report form.  
 
2.2.  Subject 
We use the following criteria to recruit subjects, i.e. Adult patients who had nosocomial infections 
in the ICU; Patients with medical records in the ICU who received antibiotics in the 2012-2014 period.  
Patients originating from inpatients (wards);  Patients with medical records were read. The exclusion criteria 
were postoperative patient and Patients with incomplete medical records. 
 
2.3. Research instruments  
We used a data collection form to collect secondary data from patient medical records,  
included name, Identification number, age, sex, date of hospital admission, hospital admission diagnosis, 
ICU admission date, ICU admission diagnosis, antibiotics used in hospitalization and ICU, bacterial culture 
data, vital signs (temperature, blood pressure, pulse, and respiration), laboratory data and patient radiology data. 
 
2.4.  Data collecting procedure  
The list of cancer patients was obtained from a hospital computer database. The patients must  
be over the age of 18 years, treated in the ICU during 2012-2014, and receiving antibiotic therapy  
to be included in the study. They were excluded if they forced to return from the ICU, and their data was 
incomplete.  Patient’s medical records who had undergone treatment at the ICU of DCSH from 2012-2014 
was selected and separated based on the inclusion and exclusion criteria by a trained health professional 
(pharmacists). Demographic (name, age, gender) data, the time and diagnosis when admitted to hospital and 
ICU, the time of the ICU discharge, the date of hospital discharge, the record of antibiotics use, and clinical 
data during hospitalization were taken from medical records. This study uses the definition of infection  
as determined by the USA central disease control (CDC) [6]. Infection is a condition (local or systemic), which is a 
reaction of the organism to the entry of or toxins released by infection-agent microorganisms.  
In this study, infection status is determined clinically based on the doctor's diagnosis, which was written  
in the medical record. Based on clinical manifestations and the doctor’s diagnosis, the frequency in each patient  
is calculated. In contrast, we obtained drug use records from the nursing and pharmacy sections. Antibiotic use 
data from medical records were then matched with those from the nursing and pharmacy. Data on infection-
causing germs were taken from the submission and delivery forms of culture examination reports.  
Subsequently, the data were recorded on the data collection form and later transferred to the case report form.  
Only patients with a complete case report form were selected and designated as subjects. Recording of patient data 
on the case report form was done anonymously, but replaced with codes, to maintain patient confidentiality. 
Int. J. Public Health Sci ISSN: 2252-8806  
 
Clinical pharmacoepidemiology of antibiotics usage in intensive care unit of cancer… (Akrom) 
171 
2.5. Ethical consideration 
The Dharmais Research ethics committee issued ethical clearance. The research protocol and 
informed consent have been reviewed and approved by the Dharmais Research ethics committee and the scientific 
committee of the Faculty of Pharmacy, Universitas Ahmad Dahlan. 
 
2.6. Data analysis 
We analyzed data descriptively in the form of percentages (frequency) for gender, age group,  
and cancer diagnosis. The antibiotics used are presented in rates by class and type. 
 
 
3. RESULTS AND DISCUSSION 
3.1.  Subject characteristic 
In the 2012-2014 period, 312 patients in the ICU were using antibiotics, but only 202 patients were 
eligible as research subjects. One hundred ten patients were excluded because of incomplete or missing 
medical records. Subjects’ demographic data are presented in Table 1.  
 
 
Table 1. Age, sex and cancer type of cancer patients in ICU 
Demographic Characteristics 
Year 
2012 n (%) 2013 n (%) 2014 n (%) 
age    
18-25 years 4 (10.8) 5 (6.9) 4 (4.3) 
25-60 years 31 (83.8) 63 (87.5) 84 (90.3) 
>60 year 2 (5.4) 4 (5.6) 5 (5.4) 
Total 37 (100) 72 (100) 93 (100) 
Sex    
Male 23 (61.2) 23 (31.9) 37 (39.8) 
Female 14 (37.8) 49 (68.1) 56 (60.2) 
Total 37 (100) 72 (100) 93 (100) 
Education     
Basic (elementary school-junior high school) 4 (10.8) 8 (11.1) 17 (18.3) 
Advanced  (senior high school-university) 33 (89.2) 64 (88.9) 76 (81.7) 
Total 37 (100) 72 (100) 93 (100) 
Marriage status    
Married 30 (81.1) 58 (80.6) 84 (90.3) 
Not married 7 (18.9) 14 (19.4) 9 (19.7) 
Total  37 (100) 72 (100) 93 (100) 
Health payment     
Personal   6 (16.2) 19 (26.4) 12 (12.9) 
Institution  8 (21.6) 9 (12.5) 8 (8.6) 
JKN insurance 23 (62.2) 44 (61.10) 73 (78.5) 
Total  37 (100) 72 (100) 93 (100) 
Job    
Labor 10 (27.0) 35 (48.6) 45 (48.4) 
Employed by the government or private sectors 27 (73.0) 37 (51.4) 48 (51.6) 
Total  37 (100) 72 (100) 93 (100) 
 
 
The number of cancer patients treated in the ICU of DCSH, Jakarta from 2012-2014,  
who met the inclusion criteria was 202. The number of cancer patients tends to increase every year.  
Descriptive analysis of the patients’ characteristics shows that the number of male patients was lower than 
that of females, with 83 (41.1%) and 119 (58.9%), respectively. In terms of age, the majority of patients were 
between 18 and 45 years with a total of 104 patients (51.5%), while patients with senior high  
school-university education outnumbered those with junior high school or elementary school (82% compared  
to 12%). Based on the age, gender, and educational background, it is known that most cancer patients who 
require treatment with antibiotics in the ICU were productive age (25-65years) women with senior high 
school-university education. This finding not only illustrates that women in the fertile period seem to be more 
susceptible to infection, but it also shows that the level of health in Indonesia is still generally low.  
The study revealed that the public health level of productive age in Indonesia is below the government's 
targets and expectations. Promotive and preventive efforts are required primarily to increase awareness, 
willingness, and ability of the public to engage in a healthy lifestyle to avoid cancer from an early age  
as an investment for the development of human resources who are socially and economically productive [21, 22]. 
 
3.2. Clinical characteristics 
Table 2 present the primary diagnosis and the patients’ clinical symptoms. We can see that most of 
the patients were diagnosed with leukemia and mammary cancer, and most of them (>50%) were treated  
in the ICU for less than fifteen days, with only a small percentage staying in the ICU for more than 15 days.  
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Based on the data, patients who most frequently suffered from infections were blood cancers (leukemia), 
lung cancer, and cervical cancer. In contrast, the most common types of diseases that affected  
The patients were lung infection (pneumonia), central venous infections, urinary tract infections,  
and wounds. The results are consistent with the general pattern of cancer in Indonesia and the type  
of infection in ICU [23, 24].  
The group and type of antibiotics used for the treatment of infections also fit the microorganism 
pattern in Indonesia. Cancer patients given antibiotics in the ICU were constantly increasing from  
2012 s.d. 2014. In 2012, 37 patients received antibiotic therapy. The figure nearly doubled in 2013 with  
72 patients and continued to grow to 92 patients in 2014. Based on the cancer types, most patients had 
leukemia, mammary cancer, and cervical cancer. The patients were given antibiotics due to pneumonia 
(52%-59%), central infection (20%-26%), urinary tractus infection UTI (11%-19%) and wounds (1%-3%). 
Most of them suffered from more than one infection with an average of more than one infection incidence 
(1.24 in 2012, 1.1 in 2013, and 1.25 in 2014). The pattern of infection events in the DCSH ICU is consistent 
with the pattern of infections in the ICU of previous studies [3, 24, 25]. 
 
 
Table 2. The primary and additional diagnosis of antibiotic use indications among the cancer patients  
Clinical characteristics 
Year 
2012 n (%) 2013 n (%) 2014 n (%) 
Type of Cancer Diagnosis    
Leukemia (AML, ALL, CLL, LGK) 7 (18.9) 11 (15.3) 23 (24.7) 
Mammae cancer 5 (13.5) 13 (18.1) 17 (18.3) 
Servix cancer 1 (2.7) 7 (9.7) 11 (11.8) 
Non-Hodgkin lymphoma 2 (5.4) 10 (13.9) 7 (7.5) 
Lung cancer 7 (18.9) 6 (8.3) 6 (6.5) 
Ovary cancer  1 (2.7) 2 (2.8) 4 (4.3) 
Nasopharynx cancer 0 (0) 5 (6.9) 2 (2.2) 
Thyroid cancer 1 (2.7) 4 (5.6) 1 (1.1) 
Colon cancer 0 (0) 1 (1.4) 5 (5.4) 
Abdomen cancer 0 (0) 4 (5.6) 4 (4.3) 
Frontal tumor 3 (8.1) 0 (0) 4 (4.3) 
Tongue cancer 1 (2.7) 1 (1.4) 1 (1.1) 
Prostat & testis cancer  3 (8.1) 1 (1.40) 0 (0) 
Astrochytoma  2 (5.4) 1 (1.4) 1 (1.1) 
Others  4 (10.8) 7 (7.4) 7 (7.7) 
Total 37 (100) 72(100) 93 (100) 
Leukocytosis status in the ICU    
Leukocytosis  26 (70.3) 50 (69.4) 65 (69.9) 
Not  leukocytosis 11 (29.7) 22 (30.6) 28 (30.1) 
Total   37 (100) 72 (100) 93 (100) 
Infection diagnosis    
Pneumonia  24 (52.2) 47 (59.5) 69 (59.5) 
UTI 9 (19.6) 9 (11.4) 21 (18.1) 
Infection central  12 (26.1) 20 (25.3) 24 (20.6) 
Wound 1 (2.2) 3 (3.8) 2 (1.8) 
Total  46 (100) 79 (100) 116 (100) 
Mean of infection diagnosis per patients  1.24 1.1 1.25 
Duration in ICU care    
<5 day 24 (64.9) 37 (51.4) 60 (64.5) 
5-15 day 10 (27.0) 24 (33.3) 24 (25.8) 
>15 day 3 (8.1) 11 (15.3) 9 (9.7) 
Total  37 (100) 72 (100) 93 (100) 
 
 
3.3. Use of group-based antibiotics 
The group of antibiotics (AB) prescribed to the patients and their various indications from 2012  
to 2014 are presented in Table 3. Meropenem was the most frequently prescribed among all antibiotics 
accounted for 27.3% in 2012, 29.5% in 2013, and 38.6% in 2014. During the three years,  
meropenem prescription reached as high as 33.8% of the total antibiotic prescriptions for infections in cancer 
patients. Research data also shows that there were fluctuations in the number of antibiotic types prescribed  
to the patients with 20, 26, and 23 types for 2012, 2013, and 2014 respectively. The pattern of antimicrobial 
use in the DCSH ICU is under the pattern of antibiotic use as a result of research in Lebanon [20], China [4], 
and Korea [23], which is experiencing fluctuations in the number and type of antibiotics. From the data  
in Table 3, it is known that the use of antibiotics in Indonesia is more than the use of antibiotics in the ICU 
from previous studies, which is more than 20 types of antibiotics. The last report research stated that  
the average consumption of antibiotics in the ICU was 20 types [18, 26]. Of the 202 patients admitted  
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to the ICU, most patients used more than one type of antibiotics. Following Table 2, it is known that most 
subjects have more than one type of infection. Such antibiotic combination usage can be justified  
in the following circumstances: initial treatment of patients with severe diseases, in polymicrobial infections 
to prevent the onset of resistant microorganisms, and to obtain a synergistic effect [25, 27]. 
 
 
Table 3. Group and type of antibiotics prescribed to the cancer patients 
Level and Type of Antibiotics 
Year 
2012 n (%) 2013 n (%) 2014 n (%) 
 Cephalosporin 3th Generation  group    
Ceftazidim 1 (1.5) 6 (4.5) 3 (1.8) 
Cefotaxime 2 (3.0) 3 (2.3) 3 (1.8) 
Ceftizoxim 1 (1.5) 2 (1.5) 0 (0) 
Cefoperazon 2 (3.0) 7 (5.3) 10 (5.8) 
Ceftriaxon  7 (10.6) 14 (10.6) 15 (8.8) 
 Cephalosporin 4th Generation groups    
Cefpirom 2 (3.0) 1 (0.8) 2 (1.2) 
Cefepim 0 (0) 3 (2.3) 4 (2.3) 
Combination of cephalosporin 3th Generation     
Sulbactam-Cefoperazon 2 (3.0) 4 (3.0) 4 (2.3) 
 Carbapenem groups    
Meropenem 18 (27.3) 39 (29.5) 66 (38.6) 
Doripenem 3 (4.5) 4 (3.0) 0 (0) 
 Aminoglycoside group    
Amikacin 4 (6.1) 5 (3.8) 8 (4.7) 
Gentamicin 1 (1.5) 2 (1.5) 0 (0) 
Streptomycin 0 (0) 1 (0.8) 0 (0) 
Netilmicin 0 (0) 2 (1.5) 0 (0) 
 Fluoroquinolone group    
Levofloxacin 5 (7.6) 23 (17.4) 26 (15.2) 
Ciprofloxacin 2 (3.0) 1 (0.8) 6 (3.5) 
Ofloxacin 2 (3.0) 0 (0) 0 (0) 
Moxifloxacin 0 (0) 0 (0) 2 (1.2) 
 Glycycline group    
Tigecycline 2 (3.0) 1 (0.8) 2 (1.2) 
 Derivat Imidazole group    
Metronidazole 3 (4.5) 1 (0.8) 6 (3.5) 
 Glycopeptide group    
Teicoplanin 0 (0) 1 (0.8) 1 (0.6) 
Penicilin+ Beta-Lactamase Inhibitor group    
Amoxicillin+Klavulanat Acid 0 (0) 1 (08) 0 (0) 
Tazobactam+Piperacilin 7 (10.6) 6 (45) 10 (5.8) 
Penicillin group derivates    
Amoxicillin 0 (0) 0 (0.0) 1 (0.6) 
Other  Antibiotic    
Linezolide 1 (1.5) 4 (3.0) 2 (1.2) 
Fosfomycin 0 (0) 1 (0.8) 0 (0) 
Total 66 (100.0) 132 (100.0) 171 (100.0) 
 
 
 The pattern of antibiotic use in hospitals is influenced by many factors, including germ distribution patterns, 
clinical conditions, types of services, and extraordinary conditions (epidemics) [28-29]. Covid-19 pandemic 
influences changes in disease patterns and the use of anti-infective drugs, including antibiotics in cancer patients  
in hospitals, including in the emergency room, wards, and in the ICU [30]. Cancer patients are one of the 
vulnerable groups in the COVID-19 pandemic, besides diabetics, hypertension, and cardiovascular disease, and 
dyslipidemic disease. Based on the results of the latest research, it is known that the top three most prevalence of 
cancer patients with the need to undergo treatment in hospital are lung cancer, breast cancer, and colorectal  
cancer [31]. The pattern of hospital visits with cancer patients' research datain the pandemic phase is almost the 
same as the pattern of hospital visits of patients in the non-pandemic era, but not so with the use of anti-infective 
drugs. Research in Wuhan and Hubei showed that the highest incidence of infection in cancer patients treated  
in the ICU was pneumonia due to SARS COV-2 infection with septic shock. The main anti-infective drugs for 
patient care in the ICU are antivirals, and more than 84% of patients get intravenous antibiotics [32-33]. Germs that 
cause lung infections in the COVID-19 pandemic are viruses, in contrast to non-pandemic conditions where the 
most significant cause of pneumonia in cancer patients is bacteria. 
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 The pattern of using antibiotics results of this study when compared with the pattern of antibiotics use 
of cancer patients in the emergency department (ED) there are differences. Patients cancer in the ED received 
beta-lactam (86.7%) anti-pseudomonal (13.6%), vancomycin aminoglycosides (9.6%) and carbapenem 
(3.2%). The pattern of the incidence of infection in cancer patients in ICU-DCSH is slightly different from 
the prevalence of infection in cancer patients from the results of a recent study conducted in the ED.  
The results of the study of the incidence of infections in cancer patients treated in the ED were mostly 
respiratory infections, then followed by skin infections and digestive tract infections. At the same time,  
the incidence of infection in cancer patients in DCSH is pneumonia, then followed by central infection  




Meropenem is the most commonly prescribed antibiotic for cancer patients in the ICU of DCSH, 
followed by levofloxacin and ceftriaxone. An increase in prescribing antibiotics meropenem, ceftriaxone,  
and levofloxacin from 2012-2014. Most infectious diseases that use antibiotics in the ICU of DCSH are 
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